Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study. uri icon

authors

  • Dejan Jakimovski MD, PhD
  • Eckert, Svetlana P
  • Mirmosayyeb, Omid
  • Thapa, Sangharsha
  • Pennington, Penny
  • Hojnacki, David
  • Weinstock-Guttman, Bianca

publication date

  • January 1, 2023